The promise of immunotherapy in head and neck squamous cell carcinoma

Annals of Oncology

Volumn 27, Issue 9, 2016, Pages 1675-1685

  Economopoulou, P ^a   Agelaki, S ^b,c   Perisanidis, C ^d   Giotakis, E I ^e   Psyrri, Amanda ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

Head and neck cancer; HPV; Immune escape; Immunotherapy

Indexed keywords

BACTERIAL VACCINE; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DNA VACCINE; DURVALUMAB; ENOBLITUZUMAB; EPACADOSTAT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PACLITAXEL POLIGLUMEX; PALBOCICLIB; PATRITUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; SCATTER FACTOR; TIVANTINIB; TUMOR NECROSIS FACTOR; UTOMILUMAB; VARLILUMAB; VASCULOTROPIN; VORINOSTAT;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INNATE IMMUNITY; IONIZING RADIATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UPREGULATION; HEAD AND NECK TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; PAPILLOMAVIRIDAE; T-LYMPHOCYTES;

EID: 84995691223     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw226     Document Type: Article

References (63)

1. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101(6): 412-423.
2. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24(5): 736-747.
3. Baxi S, Fury M, Ganly I, Rao S, Pfister DG. Ten years of progress in head and neck cancers. J Natl Compr Canc Netw 2012; 10(7): 806-810.
4. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21(2): 137-148.
5. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2014; 2: 14.
6. Spranger S, Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer 2013; 1: 16.
7. Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-Tcell-inflamed tumor microenvironment. Semin Oncol 2015; 42(4): 663-671.
8. Schoenfeld JD. Immunity in head and neck cancer. Cancer Immunol Res 2015; 3 (1): 12-17.
9. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004; 53(10): 865-878.
10. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumorinfiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8 (10): 3137-3145.
11. Hoffmann TK, Dworacki G, Tsukihiro T et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8(8): 2553-2562.
12. van der Burg SH. Immunotherapy of human papilloma virus induced disease. Open Virol J 2012; 6: 257-263.
13. Lyford-Pike S, Peng S, Young GD et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73(6): 1733-1741.
14. Badoual C, Hans S, Merillon N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73(1): 128-138.
15. Vasilakopoulou M, Velcheti V, Rampias T, Sasaki C et al. Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma. J Clin Oncol 2013; 31 (Suppl): abstr 6012.
16. Ward MJ, Thirdborough SM, Mellows T et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 2014; 110 (2): 489-500.
17. Vassilakopoulou M, Avgeris M, Velcheti V et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res 2016; 22(3): 704-713.
18. Uppaluri R, Dunn GP, Lewis JS, Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 2008; 8: 16.
19. Balermpas P, Rodel F, Rodel C et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer 2016; 138(1): 171-181.
20. Balermpas P, Michel Y, Wagenblast J et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014; 110(2): 501-509.
21. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010;2010:701657.
22. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 2005; 33(2): 113-133.
23. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006; 12(13): 3890-3895.
24. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015; 33(29): 3293-3304.
25. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013; 49(12): 1089-1096.
26. Allen C, Duffy S, Teknos T et al. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007; 13(11): 3182-3190.
27. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014; 50(7): 627-632.
28. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27: 591-619.
29. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10(11): 3755-3762.
30. Turksma AW, Bontkes HJ, van den Heuvel H et al. Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis 2013; 19(6): 577-584.
31. Baruah P, Lee M, Odutoye T et al. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology 2012; 217(7): 669-675.
32. Varilla V, Atienza J, Dasanu CA. Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther 2013; 13(9): 1241-1256.
33. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13 (21): 6301-6311.
34. Sega EI, Leveson-Gower DB, Florek M et al. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One 2014; 9(1): e86551.
35. Hekim N, Cetin Z, Nikitaki Z, Cort A, Saygili EI. Radiation triggering immune response and inflammation. Cancer Lett 2015; 368(2): 156-163.
36. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci 2014; 15(1): 927-943.
37. Zhou D, Yu T, Chen G et al. Effects of NF-kappaB1 (p50) targeted gene disruption on ionizing radiation-induced NF-kappaB activation and TNFalpha, IL-1alpha, IL-1beta and IL-6 mRNA expression in vivo. Int J Radiat Biol 2001; 77(7): 763-772.
38. Son EW, Rhee DK, Pyo S. Gamma-irradiation-induced intercellular adhesion molecule-1 (ICAM-1) expression is associated with catalase: activation of Ap-1 and JNK. J Toxicol Environ Health A 2006; 69(24): 2137-2155.
39. Akashi M, Hachiya M, Koeffler HP, Suzuki G. Irradiation increases levels of GM-CSF through RNA stabilization which requires an AU-rich region in cancer cells. Biochem Biophys Res Commun 1992; 189(2): 986-993.
40. Meirovitz A, Kuten M, Billan S et al. Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer-a prospective pilot study. Radiat Oncol 2010; 5: 16.
41. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124(2): 687-695.
42. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21(1): 15-25.
43. Potapov SL, Korman DB, Shamaev VI, Ershova RB, Makarov OV. Sensitivity of clonogenic cells of human ovarian ascitic cancer to antitumor drugs. Arch Geschwulstforsch 1988; 58(2): 99-104.
44. Chen J, Huang X, Huang G et al. Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm 2012; 27(3): 210-220.
45. Chang CL, Hsu YT, Wu CC et al. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res 2013; 73(1): 119-127.
46. Lesterhuis WJ, Punt CJ, Hato SV et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121(8): 3100-3108.
47. Ramakrishnan R, Assudani D, Nagaraj S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120(4): 1111-1124.
48. Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361(19): 1838-1847.
49. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117 (6): 1466-1476.
50. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354(6): 567-578.
51. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11): 1116-1127.
52. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23: 32-38.
53. Seiwert TY, Haddad RI, Gupta S et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol 2015; 33 (Suppl): abstr LBA6008.
54. Fury M, Butler M, Ou SH, Balmanoukian A et al. Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in head and neck cancer. ESMO Meeting 2014, Poster # 988PD. Abstract ID 5656. 2014.
55. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulinlike receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011; 132(3): 315-325.
56. Das R, Verma R, Sznol M et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194(3): 950-959.
57. Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther 2015; 15(10): 1135-1141.
58. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8(3): 151-160.
59. Tang C, Wang X, Soh H et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2014; 2(9): 831-838.
60. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11(2 Pt 1): 728-734.
61. Verbrugge I, Hagekyriakou J, Sharp LL et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72(13): 3163-3174.
62. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24(7): 1813-1821.
63. Hiniker SM, Chen DS, Reddy S et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012; 5(6): 404-407.